295 related articles for article (PubMed ID: 31102159)
61. Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving.
Baji P; Farkas M; Golicki D; Prevolnik Rupel V; Hoefman R; Brouwer WBF; van Exel J; Zrubka Z; Gulácsi L; Péntek M
Pharmacoeconomics; 2020 Jun; 38(6):633-643. PubMed ID: 32201921
[TBL] [Abstract][Full Text] [Related]
62. Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents.
Åström M; Rolfson O; Burström K
Appl Health Econ Health Policy; 2022 May; 20(3):383-393. PubMed ID: 35083734
[TBL] [Abstract][Full Text] [Related]
63. Health-related quality of life measured using the EQ-5D-3L: iranian population norms.
Mousavi A; Sari AA; Daastari F; Daroudi R
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):643-651. PubMed ID: 38450671
[TBL] [Abstract][Full Text] [Related]
64. EQ-5D-3L Health Status Among Homeless People in Stockholm, Sweden, 2006 and 2018.
Burström B; Irestig R; Burström K
Front Public Health; 2021; 9():780753. PubMed ID: 34988055
[No Abstract] [Full Text] [Related]
65. Norwegian population norms for the EQ-5D-5L: results from a general population survey.
Garratt AM; Hansen TM; Augestad LA; Rand K; Stavem K
Qual Life Res; 2022 Feb; 31(2):517-526. PubMed ID: 34272631
[TBL] [Abstract][Full Text] [Related]
66. Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement.
Conner-Spady BL; Marshall DA; Bohm E; Dunbar MJ; Loucks L; Al Khudairy A; Noseworthy TW
Qual Life Res; 2015 Jul; 24(7):1775-84. PubMed ID: 25555837
[TBL] [Abstract][Full Text] [Related]
67. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population.
Agborsangaya CB; Lahtinen M; Cooke T; Johnson JA
Health Qual Life Outcomes; 2014 May; 12():74. PubMed ID: 24885017
[TBL] [Abstract][Full Text] [Related]
68. Head-to-Head Comparison of EQ-5D-3L and EQ-5D-5L Health Values.
Selivanova A; Buskens E; Krabbe PFM
Pharmacoeconomics; 2018 Jun; 36(6):715-725. PubMed ID: 29623559
[TBL] [Abstract][Full Text] [Related]
69. Health status of the advanced elderly in six European countries: results from a representative survey using EQ-5D and SF-12.
König HH; Heider D; Lehnert T; Riedel-Heller SG; Angermeyer MC; Matschinger H; Vilagut G; Bruffaerts R; Haro JM; de Girolamo G; de Graaf R; Kovess V; Alonso J;
Health Qual Life Outcomes; 2010 Nov; 8():143. PubMed ID: 21114833
[TBL] [Abstract][Full Text] [Related]
70. EQ-5D Scores for Diabetes-Related Comorbidities.
Sullivan PW; Ghushchyan VH
Value Health; 2016 Dec; 19(8):1002-1008. PubMed ID: 27987626
[TBL] [Abstract][Full Text] [Related]
71. Experience-based health state valuation using the EQ VAS: a register-based study of the EQ-5D-3L among nine patient groups in Sweden.
Teni FS; Burström K; Devlin N; Parkin D; Rolfson O;
Health Qual Life Outcomes; 2023 Apr; 21(1):34. PubMed ID: 37038172
[TBL] [Abstract][Full Text] [Related]
72. Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community-based survey in China.
Jin X; Liu GG; Gerstein HC; Levine MAH; Guan H; Li H; Xie F
Diabetes Metab Res Rev; 2018 Nov; 34(8):e3053. PubMed ID: 30064154
[TBL] [Abstract][Full Text] [Related]
73. A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA.
Clemens S; Begum N; Harper C; Whitty JA; Scuffham PA
Qual Life Res; 2014 Oct; 23(8):2375-81. PubMed ID: 24676898
[TBL] [Abstract][Full Text] [Related]
74. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.
Gray LA; Wailoo AJ; Hernandez Alava M
Value Health; 2018 Dec; 21(12):1399-1405. PubMed ID: 30502783
[TBL] [Abstract][Full Text] [Related]
75. Quantifying the Relationship between Capability and Health in Older People: Can't Map, Won't Map.
Franklin M; Payne K; Elliott RA
Med Decis Making; 2018 Jan; 38(1):79-94. PubMed ID: 29056069
[TBL] [Abstract][Full Text] [Related]
76. Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Hakimi Z; Herdman M; Pavesi M; Devlin N; Nazir J; Hoyle C; Odeyemi IA
Qual Life Res; 2017 May; 26(5):1187-1195. PubMed ID: 27896711
[TBL] [Abstract][Full Text] [Related]
77. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
78. A Comparison of the EQ-5D-3L and EQ-5D-5L.
Thompson AJ; Turner AJ
Pharmacoeconomics; 2020 Jun; 38(6):575-591. PubMed ID: 32180162
[TBL] [Abstract][Full Text] [Related]
79. Comparison of contemporaneous responses for EQ-5D-3L and Minnesota Living with Heart Failure; a case for disease specific multiattribute utility instrument in cardiovascular conditions.
Kularatna S; Byrnes J; Chan YK; Carrington MJ; Stewart S; Scuffham PA
Int J Cardiol; 2017 Jan; 227():172-176. PubMed ID: 27865116
[TBL] [Abstract][Full Text] [Related]
80. Could the EQ-5D-3L predict all-cause mortality in older Chinese? Evidence from a 5-year longitudinal study in eastern China.
Pan CW; Liu RJ; Yang XJ; Ma QH; Xu Y; Luo N; Wang P
Qual Life Res; 2021 Oct; 30(10):2887-2894. PubMed ID: 34028640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
